News
Hims & Hers Health stock falls as Novo Nordisk expands legal battle
Investing.com -- Hims & Hers Health (NYSE: HIMS) stock edged lower on Tuesday, extending its 10% decline following disappointing earnings, as Novo Nordisk (NYSE: NVO) announced 14 new lawsuits targeting companies involved in producing and marketing compounded semaglutide products.
Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...
We recently published 10 Stocks Hit by Painful Plunge. Novo Nordisk A/S (NYSE:NVO) is one of the best-performing stocks on ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Revenue at the unit, which houses AMD’s all-important artificial intelligence chips that are viewed as central to the company ...
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.
Novo Nordisk A/S (NYSE: NVO) is one of the top cheap pharmaceutical stocks to buy now. On August 1, Bernstein analyst Florent ...
Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers and acquirers of Novo Nordisk A/S (NYSE: NVO) securities between May ...
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S ...
Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down ...
President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback